close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoVibronix, Inc. - Common Stock (NQ:NAOV)

5.885 -0.005 (-0.08%)
Streaming Delayed Price Updated: 12:33 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NanoVibronix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
NanoVibronix Launches “Oscar” Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Reverse Stock Split
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock
From NanoVibronix, Inc.
Via Business Wire
Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Valuation, Nasdaq Compliance Etc. – More Stocks Inside
Via AB Newswire
Topics Regulatory Compliance
NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement
From NanoVibronix, Inc.
Via Business Wire
ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces CEO Transition
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Responds to False Post
From NanoVibronix, Inc.
Via Business Wire
Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Results from UroShield™ Case Series
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Regains Nasdaq Compliance
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia
From NanoVibronix, Inc.
Via Business Wire
Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Reverse Stock Split
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Provides Business Update
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Signs Letter of Intent with Potential New Distributor
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
From NanoVibronix, Inc.
Via Business Wire
NanoVibronix Issues Letter to Stockholders
From NanoVibronix, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today